| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 02/01/2011 | CA2476298C Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/27/2011 | WO2011011252A1 Methods of attenuating the loss of functional status |
| 01/27/2011 | WO2011010682A1 Sterol derivative |
| 01/27/2011 | US20110021612 Nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/27/2011 | US20110021586 Phenyl-sulfamates as aromatase inhibitors |
| 01/27/2011 | US20110021480 17-beta HSD1 and STS Inhibitors |
| 01/27/2011 | US20110021462 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, and methods for the production and use thereof |
| 01/27/2011 | US20110021437 Method for reducing pain with ziconotide and baclofen |
| 01/27/2011 | US20110021413 Methods of suppressing microglial activation |
| 01/27/2011 | US20110020463 Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain caused by muscle spasm |
| 01/27/2011 | US20110020372 Follistatin domain containing proteins |
| 01/27/2011 | US20110020342 Igf-1 fusion polypeptides and therapeutic uses thereof |
| 01/27/2011 | US20110020330 Antibody inhibitors of gdf-8 and uses thereof |
| 01/27/2011 | CA2768471A1 Methods of attenuating the loss of functional status |
| 01/26/2011 | EP2278004A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 01/26/2011 | EP2277526A1 Pharmaceutical composition with tetrahydroisohumulone |
| 01/26/2011 | EP2276494A1 Stable aqueous compositions comprising bioactive creatine species |
| 01/26/2011 | EP1828221B1 Pure rocuronium bromide |
| 01/26/2011 | EP1581649B1 Binding agents which inhibit myostatin |
| 01/26/2011 | EP1496892B1 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 01/26/2011 | CN101955505A Novel immune suppressor and composition thereof |
| 01/26/2011 | CN101954053A Traditional Chinese medicinal patch and preparation method thereof |
| 01/25/2011 | US7875712 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid |
| 01/25/2011 | US7875611 Ion channel modulating compounds and uses thereof |
| 01/25/2011 | US7875585 Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide |
| 01/25/2011 | US7875279 intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis are enriched by deleting or inactivating genes; asthma, morbus Crohn, colitis ulcerosa, multiple sclerosis and chronic bronchitis and immune and auto-immune diseases and allergies and bone diseases and osteoporosis |
| 01/25/2011 | CA2388468C Mediators of hedgehog signalling pathways, compositions and uses related thereto |
| 01/25/2011 | CA2385322C A substantially cell membrane impermeable compound and use thereof |
| 01/25/2011 | CA2381882C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/20/2011 | WO2011009075A2 Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 01/20/2011 | WO2011007866A1 Agent for treatment of myotonic dystrophy |
| 01/20/2011 | WO2011007794A1 Zeolite and sericite-containing composition for medical or medical assisting uses |
| 01/20/2011 | US20110015253 Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| 01/20/2011 | US20110015235 Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors |
| 01/20/2011 | US20110015212 Pyrimidinones as pi3k inhibitors |
| 01/20/2011 | US20110015165 Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| 01/20/2011 | US20110015155 Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses |
| 01/20/2011 | US20110015116 Method for treating muscular dystrophy |
| 01/20/2011 | US20110014282 Pharmaceutical composition for poorly soluble drugs |
| 01/20/2011 | US20110014251 Microvesicles |
| 01/20/2011 | US20110014212 Certain Chemical Entities, Compositions and Methods |
| 01/20/2011 | US20110014159 Method for obtaining characterized muscle-derived cell populations and uses |
| 01/20/2011 | US20110014153 Reinforced tissue graft |
| 01/20/2011 | CA2768368A1 Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 01/19/2011 | EP2275557A1 Albumin fusion proteins |
| 01/19/2011 | CN101951916A Use of 25-hydroxy-vitamin D3 to affect human muscle physiology |
| 01/19/2011 | CN101948464A 3,4,6-triaryl-(1,3)-oxazine-2-ketone compound as well as preparation method and application thereof |
| 01/19/2011 | CN101947306A Treatment of T-cell mediated diseases |
| 01/18/2011 | US7872142 Coumarin derivatives useful as TNFα inhibitors |
| 01/18/2011 | US7872112 comprising rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A),deoxyhypusine synthase (DHS) nucleic acids and polypeptides; human cytomegalovirus immediate-early promoter/enhancer |
| 01/18/2011 | US7872094 using polypeptide comprising a membrane translocation domain and a NF- kappa B Essential Modulator (NEMO) binding sequence; comprising a NEMO binding domain (NBD) |
| 01/18/2011 | US7871984 Suppress the immunoreactivity of a CpG motif and preventing and treating immune-mediated diseases such as arthritis |
| 01/18/2011 | US7871644 Mixture of drug, aminoacrylate polymer and acid |
| 01/18/2011 | CA2432077C Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
| 01/18/2011 | CA2331460C Heterocyclic inhibitors of p38 |
| 01/18/2011 | CA2321881C Non-imidazole alkylamines as histamine h3-receptor ligands and their therapeutic applications |
| 01/13/2011 | WO2011004911A1 Method of inducing differentiation from pluripotent stem cells to skeletal muscle progenitor cells |
| 01/13/2011 | WO2011003129A1 Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers |
| 01/13/2011 | US20110009631 Phenethanolamine Derivatives for Treatment of Respiratory Diseases |
| 01/13/2011 | US20110009625 Novel compounds |
| 01/13/2011 | US20110009346 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 01/13/2011 | US20110008432 Method for Treating a Patient in Need of Aspirin Therapy |
| 01/13/2011 | US20110008375 Uses of Myostatin Antagonists |
| 01/13/2011 | US20110008338 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008337 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008336 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008296 Muscle-derived cells having differentiation capacities |
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/12/2011 | EP2272864A2 Binding agents which inhibit myostatin |
| 01/12/2011 | EP1490357B1 Toluene solvate of darifenacin |
| 01/12/2011 | CN101942393A Huperzia serrata endophytic fungus shiraia sp. strain for producing huperzine A |
| 01/12/2011 | CN101940725A Chinese medicinal preparation for treating muscular dystrophy |
| 01/12/2011 | CN101940691A Chinese traditional medicine for regulating sexual function and treating lumbar muscle strain |
| 01/12/2011 | CN101426490B Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance |
| 01/11/2011 | US7868002 Deazapurines and uses thereof |
| 01/11/2011 | US7867973 comprises follistatin domain I; free of an amino acid sequence represented by formula (I): Cys-(X1)a-Cys-(X2)b-Cys-(X3)c-Cys-(X4)d-Cys-(X5)e-Cys-(X6)f-Cys-(X7)g-Cys-(X8)h-Cys-(X9)i-Cys [x=natural amino acids]; inhibiting GDF-8 activity without inhibiting activin activity |
| 01/11/2011 | CA2487973C Method for preparing 1,3,5-triaminobenzene and hydrolyzing it into high-purity phloroglucinol |
| 01/11/2011 | CA2469876C Benzothiazoles |
| 01/11/2011 | CA2439756C Substituted aminodicarboxylic acid derivatives with pharmaceutical properties |
| 01/11/2011 | CA2420592C Fused pyrrolocarbazoles against inflammation |
| 01/11/2011 | CA2387095C Compound with growth hormone releasing properties |
| 01/06/2011 | WO2011002525A1 Methods for treatment of muscular dystrophy |
| 01/06/2011 | WO2011002520A2 Small molecule inhibitors of parp activity |
| 01/06/2011 | WO2010121225A3 Method of treating disorders associated with protein kinase ck2 activity |
| 01/06/2011 | WO2009144093A8 Hydroxytyrosol benefits mitochondria |
| 01/06/2011 | US20110004949 Immunoglobulin 1 |
| 01/06/2011 | US20110004948 Immunoglobulin 2 |
| 01/06/2011 | US20110004169 Preparation and Use of Sleeve and Micro-Encapsulated Topical Analgesic Patch For Treating Pain |
| 01/06/2011 | US20110003870 Method of treatment of a neurological disorder |
| 01/06/2011 | US20110003843 Novel compounds derived from indole and pharmaceutical compositions containing them |
| 01/06/2011 | US20110003824 Caspase Inhibitors and Uses Thereof |
| 01/06/2011 | US20110003756 C5a Receptor Antagonists |
| 01/06/2011 | US20110003388 processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient; making an enhanced, autologous fat graft comprising supplementing a first portion of extracted adipose tissue with an additive and a disaggregated population of adipose-derived cells |
| 01/06/2011 | US20110002931 Bispecific antibodies that bind to complement proteins |
| 01/06/2011 | US20110002914 Hybrid tetnus toxoid proteins that migrate retrogradely and transynaptically into the cns |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
| 01/05/2011 | EP2269609A2 Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| 01/05/2011 | EP1401467B1 Alpha-fetoprotein peptides and uses thereof |